Войти в систему Зарегистрироваться бесплатно

Neovacs S.A EV/EBITDA

Что обозначает EV/EBITDA в Neovacs S.A?

EV/EBITDA Neovacs S.A. является 3.93

Какое определение для EV/EBITDA?



EV / EBITDA - это стоимость предприятия, деленная на прибыль до вычета процентов, налогов, обесценивания и амортизации. При помощи неё измеряется, насколько дорогой является акция, и она более действительна для сравнения компаний, чем для соотношения цены и прибыли. Она измеряет цену (в форме стоимости предприятия), которую инвестор платит в пользу денежного потока компании (в форме EBITDA).

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

EV/EBITDA компаний в Health Care сектор на EURONEXT по сравнению с Neovacs S.A

Что делает Neovacs S.A?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Компании с ev/ebitda похож на Neovacs S.A